GATA3 expression in estrogen receptor α-negative endometrial carcinomas identifies aggressive tumors with high proliferation and poor patient survival

American Journal of Obstetrics and Gynecology

Volumn 199, Issue 5, 2008, Pages 543.e1-543.e7

  Engelsen, Ingeborg B ^a,b   Stefansson, Ingunn M ^a   Akslen, Lars A ^a,b   Salvesen, Helga B ^a,b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

endometrial carcinoma; estrogen receptor 2(cx); GATA3; prognostic markers; steroid receptors; survival

Indexed keywords

BIOLOGICAL MARKER; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGEN RECEPTOR BETA2; PROGESTERONE RECEPTOR; PROTEIN P16; PROTEIN P53; TRANSCRIPTION FACTOR GATA 3; UNCLASSIFIED DRUG;

ADULT; AGED; ANEUPLOIDY; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; ENDOMETRIUM CARCINOMA; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYSTERECTOMY; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

EID: 54849432745     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2008.04.043     Document Type: Article

References (28)

1. Shang Y. Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis. Nat Rev Cancer 6 (2006) 360-368
2. Lax S.F. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch 444 (2004) 213-223
3. Cesena T.I., Cui T.X., Piwien-Pilipuk G., et al. Multiple mechanisms of growth hormone-regulated gene transcription. Mol Genet Metab 90 (2007) 126-133
4. Kouros-Mehr H., Slorach E.M., Sternlicht M.D., and Werb Z. GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. Cell 127 (2006) 1041-1055
5. Mehra R., Varambally S., Ding L., et al. Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis. Cancer Res 65 (2005) 11259-11264
6. Parikh P., Palazzo J.P., Rose L.J., Daskalakis C., and Weigel R.J. GATA-3 expression as a predictor of hormone response in breast cancer. J Am Coll Surg 200 (2005) 705-710
7. Rhodes D.R., Yu J., Shanker K., et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 6 (2004) 1-6
8. Usary J., Llaca V., Karaca G., et al. Mutation of GATA3 in human breast tumors. Oncogene 23 (2004) 7669-7678
9. Tlsty T.D. Luminal cells GATA have it. Nat Cell Biol 9 (2007) 135-136
10. Hoch R.V., Thompson D.A., Baker R.J., and Weigel R.J. GATA-3 is expressed in association with estrogen receptor in breast cancer. Int J Cancer 84 (1999) 122-128
11. Prat J. Prognostic parameters of endometrial carcinoma. Hum Pathol 35 (2004) 649-662
12. Engelsen I.B., Stefansson I., Akslen L.A., and Salvesen H.B. Pathologic expression of p53 or p16 in preoperative curettage specimens identifies high-risk endometrial carcinomas. Am J Obstet Gynecol 195 (2006) 979-986
13. Rose P.G. Endometrial carcinoma. N Engl J Med 335 (1996) 640-649
14. Salvesen H.B., Iversen O.E., and Akslen L.A. Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: a population-based endometrial carcinoma study. J Clin Oncol 17 (1999) 1382-1390
15. Salvesen H.B., Das S., and Akslen L.A. Loss of nuclear p16 protein expression is not associated with promoter methylation but defines a subgroup of aggressive endometrial carcinomas with poor prognosis. Clin Cancer Res 6 (2000) 153-159
16. Scully R.E., Silverberg S.G., Wilkinson E.J., et al. Histological typing of female genital tract tumours. International histological classification of tumours. In: Organization W.H. (Ed) (1994), Berlin Heidelberg Springer-Verlag, Berlin (Germany)
17. Hoos A., Urist M.J., Stojadinovic A., et al. Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. Am J Pathol 158 (2001) 1245-1251
18. Kononen J., Bubendorf L., Kallioniemi A., et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4 (1998) 844-847
19. Tong Q., and Hotamisligil G.S. Developmental biology: cell fate in the mammary gland. Nature 445 (2007) 724-726
20. Elit L., and Hirte H. Current status and future innovations of hormonal agents, chemotherapy and investigational agents in endometrial cancer. Curr Opin Obstet Gynecol 14 (2002) 67-73
21. Alexieva-Figusch J., Van Putten W.L., Blankenstein M.A., Blonk-Van Der Wijst J., and Klijn J.G. The prognostic value and relationships of patient characteristics, estrogen and progestin receptors, and site of relapse in primary breast cancer. Cancer 61 (1988) 758-768
22. Oreskovic S., Babic D., Kalafatic D., Barisic D., and Beketic-Oreskovic L. A significance of immunohistochemical determination of steroid receptors, cell proliferation factor Ki-67 and protein p53 in endometrial carcinoma. Gynecol Oncol 93 (2004) 34-40
23. Creasman W.T. Prognostic significance of hormone receptors in endometrial cancer. Cancer 71 (1993) 1467-1470
24. Kleine W., Maier T., Geyer H., and Pfleiderer A. Estrogen and progesterone receptors in endometrial cancer and their prognostic relevance. Gynecol Oncol 38 (1990) 59-65
25. Hu K., Zhong G., and He F. Expression of estrogen receptors ER alpha and ER beta in endometrial hyperplasia and adenocarcinoma. Int J Gynecol Cancer 15 (2005) 537-541
26. Pertschuk L.P., Masood S., Simone J., et al. Estrogen receptor immunocytochemistry in endometrial carcinoma: a prognostic marker for survival. Gynecol Oncol 63 (1996) 28-33
27. Ludwig H. Prognostic factors in endometrial cancer. Int J Gynaecol Obstet 49 Suppl (1995) S1-S7
28. Mariani A., Sebo T.J., Katzmann J.A., et al. HER-2/neu overexpression and hormone dependency in endometrial cancer: analysis of cohort and review of literature. Anticancer Res 25 (2005) 2921-2927